Money is moving into cannabis equities at a pace the sector hasn't seen in years. The AdvisorShares Pure US Cannabis ETF (MSOS) touched its highest level of 2026 this week, with a one-year net asset value return of 103.7% that dwarfs both the North American Marijuana Index and the S&P 500. The catalyst isn't subtle: a Drug Enforcement Administration hearing later this month could determine whether cannabis moves off Schedule I entirely, and Trulieve's arrival on the New York Stock Exchange has given traders a fresh signal that the industry's plumbing is finally catching up to its ambitions.
What's striking here is how much of this rally rests on operational and regulatory mechanics rather than consumer demand growth. Trulieve, MSOS' largest holding at just over 30% of assets, restructured its business - separating medical cannabis operations from adult-use - specifically to clear the bar for a senior exchange listing. That's not a small technical maneuver. Multi-state operators have spent years locked out of national exchanges and mainstream institutional capital because of cannabis's federal status, forced instead onto over-the-counter markets with thinner liquidity and less analyst coverage. Every part of the back office, from seed-to-sale tracking systems to point-of-sale infrastructure like a Maine dispensary POS platform, has had to operate inside that constrained financial environment. A senior exchange listing changes the calculus for how these companies raise money, price debt, and plan expansion.
Schedule III and the 280E Problem
The regulatory hook driving investor enthusiasm traces back to April, when Acting Attorney General Todd Blanche moved state-licensed medical marijuana products into Schedule III and opened the door to broader rescheduling. That single move addressed one of the industry's most punishing structural burdens: Section 280E of the federal tax code, which bars businesses trafficking in Schedule I or II substances from deducting ordinary expenses like payroll, rent and interest. For dispensary operators running thin margins on wholesale pricing and compliant packaging costs, that tax exposure has historically eaten into cash flow more than any state excise tax ever could. Removing it for medical operators - with adult-use potentially following after the June 29 hearing - would materially improve free cash flow and balance-sheet strength across the sector, according to AdvisorShares. Maine dispensary POS platform
Uplisting Is the Real Prize
Here's the catch: rescheduling alone doesn't hand operators access to federal banking or interstate commerce. What it does is remove obstacles to uplisting onto senior U.S. exchanges, which in turn opens the door to institutional capital that has largely avoided the sector. Cresco Labs' newly secured $50 million revolving credit facility, arranged with a non-dilutive structure explicitly to position the company for capital markets access, is an early example of what that transition looks like in practice. Roth Capital called the broader rescheduling order "extremely favorable" for taxation, capital access, and sector investability - language that reflects genuine structural change, not just sentiment.
Reading the Upside Numbers Correctly
Analyst price targets tell an uneven story. Verano and Jushi Holdings carry the steepest theoretical upside, at 195% and 183% respectively, while Green Thumb Industries stands out among the larger holdings with 70% upside - ahead of both Trulieve and Curaleaf. That gap matters for anyone parsing this rally as more than a single-stock story. It suggests the market is pricing in sector-wide rerating, not just a Trulieve premium.
- Rescheduling to Schedule III would ease 280E tax burdens for licensed operators
- Senior exchange listings depend on structural changes like Trulieve's medical/adult-use separation
- Non-dilutive credit facilities are becoming a bridge to broader capital-markets access
- Retail sentiment on platforms like Stocktwits shows heavy bullish positioning, which carries its own volatility risk
None of this changes the fact that cannabis remains a state-by-state regulated business with strict testing, labeling, and age-verification requirements at the retail counter. Investor enthusiasm around a federal hearing shouldn't be confused with a resolved compliance environment; operators still answer to state regulators, METRC reporting mandates, and local zoning boards regardless of what happens in Washington this month.
